Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Didanosine (ddI) Clear all
Completed Phase 2 Interventional

An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

NCT00000672
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
66
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex

NCT00000657
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
13
States / cities
San Francisco, California • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

Comparison of ddI Versus Zidovudine in HIV-Infected Patients

NCT00000979
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

NCT00001066
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 11, 2026, 7:30 AM EDT
Terminated Phase 2 Interventional

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

NCT00002420
View directory record Official record
Conditions
HIV Infections
Interventions
Emivirine, Hydroxyurea, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Not applicable Interventional

Study of Anti-HIV Therapy Intensification

NCT00034086
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 11, 2026, 7:30 AM EDT
Completed No phase listed Observational

Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine

NCT00026676
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Study of Nystatin in HIV-Infected Patients

NCT00002313
View directory record Official record
Conditions
HIV Infections
Interventions
Nystatin, Didanosine
Drug
Lead sponsor
Argus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

NCT00000671
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

NCT00000814
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 20 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
65
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

NCT00000742
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

NCT01440569
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
COBI, DRV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

NCT00007202
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
4
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

NCT00002211
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

A Study of Azidothymidine in HIV-Infected Children

NCT00000982
View directory record Official record
Conditions
Encephalopathies, HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)

NCT00000781
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
95
States / cities
Birmingham, Alabama • Los Angeles, California • Pasadena, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Not applicable Interventional

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

NCT00002001
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Not applicable Interventional

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002411
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

NCT00001063
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

A Study of Efavirenz in Combination With Stavudine and Didanosine

NCT00002225
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Manhassett, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

NCT00001048
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
9
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 11, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

NCT00000916
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hydroxyurea, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
34
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 11, 2026, 7:30 AM EDT